The fact that therapies with anti-TNF antibodies (infliximab and adalimumab, approved for ulcerative colitis and Crohn’s disease; certolizumab pegol, approved for Crohn’s disease; and golimumab, approved for ulcerative colitis) are effective for IBD underscores that TNF plays a crucial role in the progression of this disease [191]. This evidence concerns the gene TNF and inflammatory bowel disease.